Literature DB >> 28187099

Serous Tubal Intraepithelial Carcinoma Associated With Extraovarian Metastases.

Stephanie Schneider1, Sebastian Heikaus, Philipp Harter, Florian Heitz, Christoph Grimm, Beyhan Ataseven, Sonia Prader, Christian Kurzeder, Thomas Ebel, Alexander Traut, Andreas du Bois.   

Abstract

OBJECTIVE: The evolving knowledge of ovarian carcinogenesis sets the stage for our understanding of high-grade serous pelvic carcinoma (HGSC). Findings in prophylactic surgery introduced serous tubal intraepithelial carcinoma (STIC) as potential precursor of HGSC. The present study explores whether STIC instead should already be considered as an early stage of HGSC with a need for comprehensive staging and therapy. PATIENTS AND METHODS: We identified all consecutive patients with HGSC who received first-line therapy in our referral center for gynecologic oncology from January 2011 to April 2016. All chemo-naive patients with upfront debulking surgery in whom an association of STIC and tumor lesions could be analyzed were included. Patients with previous removal of the adnexa or overgrown of the fallopian tube by the tumor were excluded. Pathological workup of the fallopian tubes according to the SEE-FIM protocol was conducted.
RESULTS: We analyzed a series of 231 consecutive patients with HGSC of whom 121 (52.4%) had ovarian cancer, 74 (32.0%) had cancer of the fallopian tubes and 36 patients (15.6%) had primary peritoneal cancer. Serous tubal intraepithelial carcinoma could be identified in 158 (68.4%) of 231 patients; of 22 patients, 28.1% is ovarian cancer, 30.8% cancer of the fallopian tubes, and 9.5% peritoneal cancer. Four patients without any further intra-abdominal disease were identified of whom 2 patients had stage FIGO IA and 2 patients had lymph node metastases only.
CONCLUSIONS: Our data suggest that STIC should be regarded as a malignant lesion with metastatic potential. Therefore, we recommend a comprehensive surgical staging including lymphadenectomy.

Entities:  

Mesh:

Year:  2017        PMID: 28187099     DOI: 10.1097/IGC.0000000000000920

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  The conceptual advances of carcinogenic sequence model in high-grade serous ovarian cancer.

Authors:  Hiroshi Kobayashi; Kana Iwai; Emiko Niiro; Sachiko Morioka; Yuki Yamada; Kenji Ogawa; Naoki Kawahara
Journal:  Biomed Rep       Date:  2017-07-27

2.  Reported Incidence and Survival of Fallopian Tube Carcinomas: A Population-Based Analysis From the North American Association of Central Cancer Registries.

Authors:  Britton Trabert; Sally B Coburn; Andrea Mariani; Hannah P Yang; Philip S Rosenberg; Gretchen L Gierach; Nicolas Wentzensen; Kathy A Cronin; Mark E Sherman
Journal:  J Natl Cancer Inst       Date:  2018-07-01       Impact factor: 13.506

3.  Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.

Authors:  Goli Samimi; Britton Trabert; Máire A Duggan; Jennifer L Robinson; Kisha I Coa; Elizabeth Waibel; Edna Garcia; Lori M Minasian; Mark E Sherman
Journal:  Gynecol Oncol       Date:  2018-03       Impact factor: 5.482

4.  A Resident's Perspective of Ovarian Cancer.

Authors:  Christopher G Smith
Journal:  Diagnostics (Basel)       Date:  2017-04-27

Review 5.  Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence.

Authors:  Orestis Tsonis; Fani Gkrozou; Konstantinos Vlachos; Minas Paschopoulos; Michail C Mitsis; Nikolaos Zakynthinakis-Kyriakou; Stergios Boussios; George Pappas-Gogos
Journal:  Ann Transl Med       Date:  2020-12

6.  Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).

Authors:  Philipp Harter; Jan Hauke; Florian Heitz; Alexander Reuss; Stefan Kommoss; Frederik Marmé; André Heimbach; Katharina Prieske; Lisa Richters; Alexander Burges; Guido Neidhardt; Nikolaus de Gregorio; Ahmed El-Balat; Felix Hilpert; Werner Meier; Rainer Kimmig; Karin Kast; Jalid Sehouli; Klaus Baumann; Christian Jackisch; Tjoung-Won Park-Simon; Lars Hanker; Sandra Kröber; Jacobus Pfisterer; Heidrun Gevensleben; Andreas Schnelzer; Dimo Dietrich; Tanja Neunhöffer; Mathias Krockenberger; Sara Y Brucker; Peter Nürnberg; Holger Thiele; Janine Altmüller; Josefin Lamla; Gabriele Elser; Andreas du Bois; Eric Hahnen; Rita Schmutzler
Journal:  PLoS One       Date:  2017-10-20       Impact factor: 3.240

7.  PAX8 expression in high-grade serous ovarian cancer positively regulates attachment to ECM via Integrin β3.

Authors:  Amata Amy Soriano; Tiziana de Cristofaro; Tina Di Palma; Serena Dotolo; Priyanka Gokulnath; Antonella Izzo; Gaetano Calì; Angelo Facchiano; Mariastella Zannini
Journal:  Cancer Cell Int       Date:  2019-11-20       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.